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Endogenous heparin activity is decreased in
peripheral arterial occlusive disease
Venugopal K. Shankar, FRCS(Ed), Ashok Handa, FRCS(Eng), and Linda Hands, MS, FRCS,
Oxford, United Kingdom
Background: Naturally occurring heparin-like activity in the form of endogenous heparin and heparin sulfate proteogly-
cans has been shown in normal human plasma. Exogenous low-dose heparin improves pain-free walking distance and
maximum walking distance in peripheral arterial occlusive disease (PAOD). Is reduced endogenous heparin activity
responsible for some of the problems found in PAOD? This study compared heparin-like activity in patients with PAOD
with that in healthy subjects and explored its relationship to disease severity.
Methods: In part 1, native and heparinase-modified thromboelastography was performed on peripheral venous blood samples
in three groups of patients to measure heparin-like anticoagulant activity. Group 1: 15 control subjects (median age, 60 years;
range, 49-74 years; ankle-brachial pressure index [ABPI]>0.9); group 2: 14 patients with intermittent claudication (median
age, 66 years; range, 56-80; ABPI, 0.69 [SD, 0.09]); group 3: 14 patients with rest pain (median age, 67.5 years; range, 54-84
years; ABPI, 0.45 [SD, 0.08]). In part 2, heparin equivalent to that in normal plasma was added to blood samples from 15
patients with short-distance claudication (n 4) or rest pain (n 11), and baseline (without heparinase) thromboelastogra-
phy was performed to exclude lack of antithrombin as a cause of diminished heparin-like activity.
Results: In part 1, all patients with PAOD had a significant increase in coagulability compared with controls. Heparinase-
modified thromboelastography in controls showed a significant decrease in the latent period between placing the sample in the
analyser, where it is recalcified, to the initial fibrin formation (R time; P  .002) compared with native TEG, confirming
endogenous heparin-like activity. Using R time as a measure of heparin-like activity, a significant reduction was found in
patients with claudication (0.33minutes; 95% confidence interval [CI], 0.004-0.65; P .02) and in those with rest pain (0.25
minutes; 95% CI,0.02 to 0.52; P .02) compared with that in controls (0.78 minutes; 95% CI, 0.39-1.16). The R time
also correlated with the ABPI (r 0.35, P .02), suggesting declining heparin-like activity with increasing ischemia. In part
2, exogenous heparin restored the thromboelastography in PAOD patients to normal, suggesting that lack of endogenous
heparin-like compounds rather than reduced antithrombin levels was responsible for changes in coagulation.
Conclusion: Patients with PAOD have reduced endogenous heparin-like activity that correlates with disease severity.
( J Vasc Surg 2008;47:1033-8.)
Clinical Relevance: Studies have confirmed the presence of natural heparin-like anticoagulant activity in the form of endogenous
heparin and heparan sulfate proteoglycans in normal human plasma. We know that supplementation with low-dose exogenous
heparin improves pain-free walking distance andmaximumwalking distance in peripheral arterial occlusive disease. Could some of
the pathology of peripheral arterial occlusive disease relate to an underlying lack of endogenous heparin-like activity?Endogenous heparin produced by connective tissue-type
mast cells1 and heparan sulfate proteoglycan (HSPG), a vessel
wall glycosaminoglycan from the vascular endothelial cells,2,3
constitute antithrombin-dependent, heparinase-I–sensitive
anticoagulant activity detectable in normal human plasma.4,5
Several investigators have confirmed the presence of endoge-
nous heparin activity and have quantitatively and qualitatively
assessed it in normal and pathologic states. Cavari et al5
identified an endogenous heparinase-sensitive anticoagulant
activity in plasma from healthy patients, measured by throm-
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doi:10.1016/j.jvs.2007.11.030bin time using a proteolytic digestion method, equivalent to
0.1 to 0.2 IU of standard heparin per 1 mL of plasma of
healthy subjects. Glycosaminoglycans have also been mea-
sured in nanogram quantities but have required sensitive
electrophoretic assays to detect and measure them in plasma
and other biologic fluids.6,7
The level of endogenous heparin-like activity sensitive to
heparinase is increased with trigger events such as hemor-
rhagic shock,8 infections,9 hypothermia,10 and organ trans-
plantation, especially after orthotopic liver transplantation,11
in the absence of any exogenous heparin administration. Phys-
iologically, these levels may be elevated with physical exer-
cise,12 among other variables.
Heparin augments anticoagulation activity by binding
to antithrombin (AT). It also contributes to the bleeding
time in humans and enhanced blood loss from the micro-
vasculature by its interaction with platelets and endothelial
cells,13 and increases fibrinolysis by its actions through
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dent of AT. In addition to its antihemostatic activity,
heparin increases vessel wall permeability, suppresses the
proliferation of vascular smooth muscle cells, suppresses
osteoblast formation, and activates osteoclasts.
The heparin-AT complex is the main inhibitor of coag-
ulation enzymes, including thrombin (IIa) and factors Xa,
Xia, and XIIa. Of these, thrombin and factor Xa are the
most responsive to inhibition, and human thrombin is
approximately 10-fold more sensitive than Xa to inhibition
by heparin-AT. Heparin binds to the lysyl residues on AT
and induces a conformational change, thereby converting
AT from a slow to a very rapid inhibitor of clotting en-
zymes. Antithrombin remains bound to thrombin in the
thrombin-antithrombin complex (TAT), but heparin dis-
sociates to be reused. Reduced AT and increased TAT
levels in serum are among the significant hemostatic alter-
ations found in patients with advanced peripheral vascular
disease.14 Abnormally low levels of AT found in PAOD
could be responsible for reduced thrombin inhibition even
in the presence of normal endogenous heparin levels.
Long-term intermittent heparin therapy in non-
anticoagulant doses has been shown to reduce fibrinogen
levels15 and improve claudication as well as maximum
walking distances.16,17 We hypothesized that part of the
heightened coagulation activity in atherosclerotic disease
relates to the reduced production of endogenous heparin-
like substances in these patients. We therefore set out to
measure endogenous heparin-like activity in patients with
PAOD and to identify its relationship to the severity of disease.
We also had to exclude the possibility that any apparent
reduction in heparin-like activity was due to low AT levels.
METHODS
The Ethics Committee of Oxford Radcliffe Hospitals
NHS Trust approved this study and all the patients who
Table I. Demographic and vascular risk factor details of st
Groups Control
Participants, No 15
Sex, No.
Female 2
Male 13
Age, median (range) y 60 (49-74)
ABPI (mean  SD) 1.04  0.11
Antihypertensive therapy, No. 4
Diabetes mellitus, No. 2
Smoking (current), No. 3
Hyperlipidemia treatment, No. 1
Previous event
MI, No. 0
CVA, No. 0
DVT, No. 0
Antiplatelet therapy, No. 4
ABPI, Ankle-brachial pressure index; CVA, cerebrovascular accident; DVT,participated provided informed consent.Part 1. Sequential patients presenting to the vascular
outpatient department with claudication or rest pain due to
atherosclerotic disease were asked to participate, and 14
patients with intermittent claudication (IC) and 14 patients
with rest pain were recruited. From amongst general surgi-
cal patients, 15 subjects aged45 years with no symptoms
of PAOD, an ankle-brachial pressure index (ABPI) 0.9,
and no history of cardiovascular, cerebrovascular, or malig-
nant disease were recruited. Control and patient group
demographic and vascular risk factor details for parts 1 and
2 are given in Table I.
Part 2. Also recruited were 15 patients with symptoms
of PAOD, including short-distance claudication (n  4)
and rest pain (n  11), admitted for peripheral vascular
reconstruction procedures. Patient demographic and vas-
cular risk factor details are given in Table I.
No patient in any of the groups received any form of
exogenous heparin or any other anticoagulation agent. Within
the 2 weeks before study, aspirinwasonlyantiplatelet agentused.
Baseline thromboelastography. Thromboelastogra-
phy (TEG) is a rapid, sensitive, global test of coagulation
using whole blood. It measures the viscoelastic properties
of a blood clot and provides information about the com-
bined function of all the factors involved in the process of
clot formation and its subsequent dissolution. A small
amount of whole blood (340L) is placed in a cuvette, and a
pin suspended by a torsion wire is lowered in to the sample.
The torque experienced by the pin as the clot forms is re-
corded as a trace. Five parameters—R, K, angle (), MA, and
CI—are usually measured18 (Fig 1).
● R time is the latent period between placing the sample in
the analyser, where it is recalcified, to the initial fibrin
formation; it correlates with the time to initial fibrin
formation and is used to estimate heparin like anticoag-
ulant activity in a given blood sample.19 R time is pro-
groups
Part 1
Part 2IC Rest pain
14 14 15
4 2 5
10 12 10
66 (56-80) 67.5 (54-84) 62 (56-84)
0.69  0.09 0.45  0.08 0.56  0.04
6 8 9
3 3 4
4 2 2
3 3 1
0 1 2
0 1 3
0 0 0
5 9 8
vein thrombosis; IC, intermittent claudication; MI, myocardial infarction.udylonged by anticoagulants like heparin and coagulation
n tim
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conditions.
● K time is a measure of time from the beginning of clot
formation until a fixed level of clot firmness is reached
(amplitude of 20 mm). This TEG parameter is short-
ened by increased fibrinogen level and to a lesser extent
by increased platelet activity and is prolonged by
agents that affect both.
● The  angle is the angle between the horizontal line
through the center of the TEG tracing and the line
tangential to the developing “body” of the TEG trac-
ing. The  angle represents the acceleration of fibrin
build up and cross-linking (clot strengthening). Simi-
lar to K time, the angle increases with raised fibrinogen
levels and to a lesser extent with platelet activity.
● MA, or maximum amplitude, is a direct function of the
maximum dynamic properties of fibrin and platelet
bonding by glycoprotein (GP) IIb/IIIa receptors; it
represents the ultimate strength of the fibrin clot and is
dependent on the number and function of platelets
and their interaction with fibrin.
● CI (coagulation index) describes the patient’s overall
coagulation status and is derived from the R, K, MA
and  angle of blood tracings (CI  0.245R 
0.0184K  0.1655MA  0.0241  5.0220).20
Heparinase-modified thromboelastography to mea-
sure heparin activity. We measured the change in R time
(R time) between a baseline TEG tracing and that ob-
tained from an aliquot of the same sample when exposed to
a heparinase-modified TEG protocol. This R should be
attributable to the contribution of heparin-like activity in
the original sample from substances susceptible to hepari-
nase breakdown. We used modified TEG cups containing
heparinase-I, an enzyme obtained from Flavobacterium
heparinum, which selectively breaks down the glycosami-
Fig 1. Baseline (native) thromboelastography of a venou
acceleration of fibrin buildup and cross-linking (clot stren
EPL, estimated percent lysis; G, clot firmness as shear el
lysis at 30 minutes after maximum amplitude; LY60, p
maximum amplitude (ultimate clot strength); R, reactionoglycans, heparin, and heparan sulfate. Heparinase hasbeen shown to neutralize heparin more effectively than
protamine in blood samples obtained during cardiopulmo-
nary bypass.21 This method has been shown to be both
sensitive and specific for the detection of changes due to
heparin activity compared with conventional tests of anti-Xa
activity, activated partial thromboplastin time, and activated
coagulation time.22 This technique is also used in cardiac
surgery to check the extent of heparin reversal by protamine in
postoperative patients23 and to detect increased endogenous
heparin-like activity after orthotopic liver transplantation. We
validated this method in our previous study involving patients
with PAOD and heparinase-modified TEG.24
Blood sampling. Samples were collected from the
antecubital vein without tourniquet use to avoid activation
of the coagulation cascade. Samples were stored in citrated
tubes for 1 to 2 hours and were analyzed after recalcifica-
tion using both native and heparinase-modified TEG, a
method that gives better reproducibility than immediate
analysis of a fresh sample.25
Statistical methods. The TEG data within groups were
analyzed using the Wilcoxon signed rank test. Significant
differences in TEG data between groups were sought using a
Mann-WhitneyU test. The relationship betweenR time and
ABPI was identified using the Spearman correlation test. A
value of P	 .05 considered significant (two-tailed).
RESULTS
Part 1. The baseline TEG variables showed a signifi-
cant increase in the coagulability of blood samples from
patients with symptoms of PAOD (intermittent claudica-
tion and rest pain) compared with the control group: R
time, P  .001; K time, P  .003;  angle, P  .003; MA,
P  .004; and CI, P  .004 (Table II). We also found a
significant relationship between the overall coagulability of
blood and the severity measured by the ABPI of the disease
ple from control subjects.A, Current amplitude; Angle,
ing); CI, coagulation index (overall coagulation status);
odulus; K, dynamics of clot formation; LY30, percent
t lysis at 60 minutes after maximum amplitude; MA,
e (time to initial fibrin formation).s sam
gthen
astic m
ercenin patients with PAOD (r  0.395; P  .009; Fig 2).
descr
dicatio
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showed a significant decrease in the R time compared with
the native (baseline) TEG, confirming the presence of
heparinase-I–sensitive endogenous heparin-like activity.
The same method revealed a significant reduction in R
time in blood samples from patients with PAOD, confirming
the presence of a detectable heparin-like activity in those
patients. However, the R time (endogenous heparin-like
activity) was significantly lower than in control subjects
(0.78 minutes, 95% confidence interval [CI], 0.39-1.16
minutes) in both the claudication (0.33 minutes, 95% CI,
0.004-0.65 minutes; P  .020) and the rest pain group
(0.25 minutes, 95% CI, 0.02 to 0.52 minutes; P  .016;
Fig 3). We found no significant difference in R time
between claudication and rest pain groups.
When we exposed the samples from the patients with
PAOD to heparinase, we also observed a significant nega-
tive relationship between R time and the severity of
Table II. Baseline (native) thromboelastography data for
Native TEG parameter a Controls (95% CI)
R time, min 9.40 (8.48-10.33)
Pb
K time, min 2.88 (2.52-3.23)
P
 Angle, deg 56.23 (53.51-58.95)
P
MA, mm 58.07 (55.30-60.83)
P
Coagulation index 1.06 (0.56-1.57)
P
CI, Confidence interval; IC, intermittent claudication; MA, maximum amp
aR time, latent period between placing the sample in the analyser, where i
beginning of clot formation until a fixed level of clot firmness is reached (am
of the TEG tracing and the line tangential to the developing “body” of the
and platelet bonding by glycoprotein IIb/IIIa receptors; coagulation index
bP values refer to significance of difference between control group and clau
Fig 2. Overall coagulability and peripheral ischemia.disease by the ABPI (r  0.350, P  .021) demonstratinga fall in endogenous heparin-like activity as peripheral vas-
cular disease advanced (Fig 4).
Part 2. The addition of heparin to the blood samples
from patients with PAOD led to a significant increase in the
R time of 5.84 minutes (95% CI, 4.98-6.69) vs 8.33
minutes (95% CI, 6.77-9.89, P .002) restoring coagula-
bility to that of control subjects.
DISCUSSION
We have shown that heparinase-modified TEG can
identify endogenous heparin activity in controls and pa-
tients with PAOD. We have also shown that PAOD is
associated with reduced heparin-like activity in the blood
and that the magnitude of reduction relates to the severity
of atherosclerotic disease measured by the ABI. The alter-
native explanation, that the reduced heparin-like activity is
rol, claudication, and rest pain groups
IC (95% CI) Rest pain (95% CI)
7.50 (6.52-8.42) 5.55 (4.29-6.81)
.041 .004
2.14 (1.61-2.66) 1.71 (1.29-2.13)
.020 .041
66.52 (60.64-72.39) 63.25 (58.74-67.75)
.013 .033
64.17 (59.04-69.30) 69.42 (62.34-73.50)
.033 .005
2.21 (1.29-2.91) 2.32 (1.73-3.12)
.016 .004
; TEG, thromboelastography.
calcified, to the initial fibrin formation; K time, measure of time from the
e of 20 mm);  angle, angle between the horizontal line through the center
racing; MA, a direct function of the maximum dynamic properties of fibrin
ibes the patient’s overall coagulation status.
n or rest pain group.
Fig 3. Endogenous heparin-like activity in patients with periph-
eral arterial occlusive disease. R is the change in latent period
between when the sample is recalcified and initial fibrin formation.cont
litude
t is re
plitud
TEG tdue to lack of AT rather than lack of endogenous heparin-
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to normal with a physiologic dose of exogenous heparin.
Tuman et al19 used the heparinase-modified TEG
method in 42 healthy volunteers and found no significant
endogenous heparin-like activity in most of the samples
analyzed 3 minutes after collection and citration, although
they did find some activity in a small group that they ascribed
to contamination. Ideally, blood samples should be analyzed
6 minutes after collection.26 This is often not practicable,
and samples are usually citrated and analyzed after a delay.
Camenzind et al25 investigated the effects of citrate
storage on TEG and confirmed that TEG indicators were
different in recalcified, citrated blood samples compared
with native blood. The observed changes were progressive
in samples during 0 to 30 minutes of storage but were
stable thereafter, and the authors recommend analysis after
a citrate storage period between 1 and 8 hours for reliable
TEG results. We followed this method and performed
native and heparinase-modified TEG after a citrate storage
period of 1 to 2 hours for all samples in an effort to obtain
reliable results. This may explain the difference between
our results and those of Tuman et al.19
The reduction in heparin like activity is probably related
to reduced production in the arterial wall. Studies of ath-
erosclerotic human coronary arteries have shown a reduc-
tion in HSPG proportional to the increasing severity of
atherosclerosis.27 Heparan sulfate content in the intima of
human arteries, especially in atherosclerosis-prone regions
such as coronary arteries, renal arteries, internal carotid
artery at the level of the carotid sinus, abdominal aorta, and
iliac arterial segments, has been shown to decrease with an
increase in the severity of atherosclerotic lesions.28
Reduced “heparin-like” activity has obvious implica-
tions. Endogenous heparin and HSPGs found on the neg-
atively charged29 luminal surfaces of the endothelial cells
Fig 4. Severity of peripheral arterial occlusive disease and endog-
enous heparin-like activity. R is the change in latent period
between when the sample is recalcified and initial fibrin formation.are essential for inhibition of coagulation at the endothelialsurface30 and lipoprotein lipase function,31 both of which
are defective in atherosclerotic vascular endothelium.32
Circulating endogenous heparin and heparan sulfates in the
proteoglycan layer of the intima subjacent to the lumen
bind with and activate antithrombin to form an effective
anticoagulant complex on the endothelial surface. Endog-
enous heparin has been shown to decrease microthrombi
formation at sites of endothelial injury.33
Heparin has a number of actions mediated independently
of AT. It inhibits platelet activation after flow through vessels
with a high and moderate shear stress.34 It also prevents
endothelial cell dysfunction after ischemia by augmenting
vasodilation mediated by endothelial-derived relaxing fac-
tor.35 These actions of heparin are of particular importance,
because both high shear36,37 and ischemia-induced endothe-
lial dysfunction38 are known to exist in patients with PAOD.
Studies of hemostatic factors and products of coagula-
tion show a similar trend in both cardiac and PAOD
patients, suggesting activation of coagulation. Once pa-
tients reach a stage where endogenous heparin-like activity
is significantly reduced, then the obstructive effects of
atherosclerosis on blood flow may be compounded by an
increasing tendency to thrombosis within the downstream
vessels. LMW heparins act by reducing fibrinogen level and
whole blood viscosity, especially in narrowed segments
(low flow) of the peripheral vessels. LMW heparin is anti-
thrombotic and profibrinolytic by increasing anti-Xa levels
and plasminogen activity33 and may therefore help in clau-
dication by reducing the viscosity.
A variety of heparin-related products have also been
shown to inhibit vascular smooth muscle cell proliferation
and to alter the endothelial response after vascular injury.
Exogenous heparin preparations suppress smooth muscle
cell proliferation after injury to vascular endothelium, and
LMW heparin has been shown to reduce neointimal hyper-
plasia in cultured human saphenous vein.39 Heparin in
non-anticoagulant doses has been tried in patients to re-
duce stenosis after angioplasty, but it has been difficult to
demonstrate a clear benefit.40 Inadequate levels of endoge-
nous heparin may allow excessive intimal hyperplasia at points
of trauma within the vascular system either owing to clinical
intervention or in areas of turbulence within the circulation.
Studies in which small doses of subcutaneous LMW hep-
arin (15,000 anti Xa U/d) were given to patients with PAOD,
absolute claudication time and walking distance improved
along with a significant increase in activated partial thrombo-
plastin time that nevertheless remained within normal lim-
its.17 A 3-month course of unfractionated heparin (12,500 IU
once daily) has also been shown to improve pain-free walking
distances to a greater extent than an antiplatelet agent, ticlo-
pidine, alone16 in patients with PAOD. This study provides
supporting evidence for the use of low-dose heparin in pa-
tients with PAOD. This may be particularly important at the
time of prolonged immobility and surgical intervention.
CONCLUSION
Patients with advanced PAOD exhibit reduced endog-
enous heparin-like activity, which correlates negatively with
JOURNAL OF VASCULAR SURGERY
May 20081038 Shankar, Handa, and Handsthe severity of disease. This appears to be due to lack of
endogenous heparin-like substances rather than impaired
AT activity alone.
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